Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Advertisement
Set Alert for Articles By Ramsey Baghdadi

Latest From Ramsey Baghdadi

The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?

Akcea’s volanesorsen for familial chylomicronemia syndrome barely made it through advisory committee due to a rare but unpredictable and rapidly presenting adverse event that likely can’t be resolved with a REMS. Now what? 
Advisory Committees Drug Safety

FDA Pulmonary/Rheumatology Division Sees Management Shakeup

Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of  division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.

FDA Inflammation

It's NTAP Season!

In a Pink Sheet podcast, Prevision Policy analysts discuss the US Medicare program's new technology add-on payment process.

 

Medicare Reimbursement

The Sarepta Precedent: The Good, The Bad, And The Ugly

Podcast discussion of three broader precedents stemming from US FDA's original Exondys 51 approval.

Drug Approval Standards FDA

Grading Gottlieb: A Podcast Report Card

Prevision policy experts discuss where US FDA commissioner has been most effective, room for improvement, and what would make for a second successful year.
Leadership FDA

Generics, Budgeting, And The Stubborn Persistence Of Cost Savings

ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.  
Generic Drugs Medicaid
See All
Advertisement
UsernamePublicRestriction

Register